STEPP for the EGFR inhibitor-induced rash-definitely a step in the right direction

Current Oncology Reports

Volumn 12, Issue 4, 2010, Pages 223-225

  Coleman, Shawnta ^a   Jatoi, Aminah ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYDROCORTISONE; PANITUMUMAB; STEROID; SUNSCREEN;

CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; HUMAN; HYPOMAGNESEMIA; INTERVENTION STUDY; METASTASIS; NOTE; OPEN STUDY; PLACEBO EFFECT; QUALITY OF LIFE; RISK REDUCTION; SKIN CARE; SKIN TOXICITY; VULNERABLE POPULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; EMOLLIENTS; EXANTHEMA; GLUCOCORTICOIDS; HUMANS; PREMEDICATION; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUNSCREENING AGENTS;

EID: 77956392947     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0102-7     Document Type: Note

References (4)

1. Solomon BM, Jatoi A: Rash from EGFR inhibitors: Opportunities and challenges for palliation. Curr Oncol Rep 2008, 10:304-308.
2. Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Oncology 2007, 21:34-36.
3. Scope A, Agero AL, Dusza SW, et al.: Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25:5390-5396.
4. Jatoi A, Rowland K, Sloan JA, et al.: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008, 113:847-853.